Neurotech expands exclusive license to include all neurological disorders
Finfeed Archived Mar 02, 2021
Neurotech International Limited (ASX: NTI) has expanded its exclusive license with Dolce Cann Global Pty Ltd to now include all neurological disorders, disease or affliction affecting the human brain function, specifically - Autism, Epilepsy, ADHD, Alzheimer’s disease, Huntington’s disease, Multiple Sclerosis, Transverse Myelitis, Inflammatory Brain disease, Fibromyalgia, Chronic Fatigue and Migraine.
Embark Health licence approvals bode well for MMJ Group
Finfeed Archived Apr 28, 2020
MMJ Group has provided an update on licence approvals for Embark Health, whose BC facility has now received all occupancy and business licences required from the city of Delta, BC, and will commence the extraction of cannabis in April 2020.